Overview

A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue Sarcoma

Status:
Not yet recruiting

Trial end date:
2024-12-30

Target enrollment:

Participant gender:

Summary

This is a single arm, open label, phase 2 study aimed to evaluate the efficacy and safety of the combination recombinant anti-PD-1 humanized monoclonal antibody injection (609A) and doxorubicin hydrochloride in the treatment of metastatic/unresectable non-specific soft tissue sarcoma

Phase:

Phase 2

Details

Lead Sponsor:

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Treatments:

Doxorubicin
Liposomal doxorubicin